albiglutide
Trade name: tanzeum
Approved
Apr 15, 2014
Albiglutide is a glucagon-like peptide-1 agonist drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018. — Wikipedia
Clinical trial activity
37 trials · 6 clinical orgs · 1 marketing orgs
Earliest trial started Feb 1, 2006 (NCT00354536)
Timeline
2000s
- Jan 1, 2006
GlaxoSmithKline — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2006
GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2009
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
2010s
- Apr 15, 2014
GlaxoSmithKline — Earliest FDA Approval
- Apr 15, 2014
GlaxoSmithKline — NDA Organization
- Apr 15, 2014
GlaxoSmithKline — Marketing Organization
Indications
Approved for
Mechanism of action
GLP1R agonist
Approval history
- approvedApr 15, 2014
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaAlbiglutide ↗
- NCATS5E7U48495E ↗
- ChEMBLCHEMBL2107841 ↗
Also known as
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albiglutide
- albugon
- eperzan
- eperzan
- eperzan
- gsk716155
- gsk716155
- gsk716155
- gsk716155
- gsk-716155
- rglp-1 protein
- tanzeum
- tanzeum
- tanzeum
- tanzeum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03015519 | Phase 3 | Aug 14, 2017 | GlaxoSmithKline |
| NCT02750930 | Phase 4 | Oct 7, 2016 | GlaxoSmithKline |
| NCT02793154 | Phase 4 | Sep 26, 2016 | GlaxoSmithKline, Wake Forest University |
| NCT02802514 | Phase 4 | Sep 20, 2016 | GlaxoSmithKline, Harvard University |
| NCT02787551 | Phase 3 | Jul 6, 2016 | Sanofi |
| NCT02683746 | Phase 3 | Mar 16, 2016 | GlaxoSmithKline |
| NCT02660736 | Phase 1 | Feb 1, 2016 | GlaxoSmithKline |
| NCT02229240 | Phase 3 | Aug 1, 2015 | GlaxoSmithKline, PPD |
| NCT02465515 | Phase 4 | Jul 1, 2015 | Duke University, GlaxoSmithKline |
| NCT02496221 | Phase 4 | Jun 1, 2015 | GlaxoSmithKline |
| NCT02229227 | Phase 3 | Dec 1, 2014 | GlaxoSmithKline, PPD |
| NCT02284009 | Phase 2 | Oct 1, 2014 | GlaxoSmithKline |
| NCT01777282 | Phase 3 | Feb 23, 2013 | GlaxoSmithKline |
| NCT01733758 | Phase 3 | Feb 1, 2013 | GlaxoSmithKline |
| NCT01475734 | Phase 2 | Dec 1, 2011 | GlaxoSmithKline |
| NCT01406262 | Phase 1 | Jul 6, 2011 | GlaxoSmithKline |
| NCT01357889 | Phase 2 | Jul 1, 2011 | GlaxoSmithKline |
| NCT01357850 | Phase 2 | Sep 1, 2010 | GlaxoSmithKline |
| NCT01147718 | Phase 1 | Jun 11, 2010 | GlaxoSmithKline |
| NCT01147731 | Phase 1 | Jun 4, 2010 | GlaxoSmithKline |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 36 | 36 | 4 | 2006 |
| PPD | For profit | 2 | 0 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sanofi | For profit | 1 | 1 | 1 | 2016 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2016 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA | Apr 15, 2014 |
| GlaxoSmithKline | For profit | MKTG | Apr 15, 2014 |